Therapy Areas: AIDS & HIV
Gilead Show 96-Week Results from Phase 3 Study of Biktarvy for the Treatment of HIV-1 in Adults New to HIV Therapy
4 October 2018 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has received 96-week results from a Phase 3, randomised, double-blinded study (Study 1489) evaluating the safety and efficacy of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) for the treatment of HIV-1 infection in treatment-naïve adults, the company said.
In the ongoing study, Biktarvy was found to be statistically non-inferior to a regimen of abacavir/dolutegravir/lamivudine (600/50/300mg, ABC/DTG/3TC) through 96 weeks of therapy. The data will be presented during a late-breaking abstract session at the IDWeek 2018 conference in San Francisco.
Biktarvy is indicated in the US as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those adults who are virologically suppressed (HIV-1 RNA
Login
Username:

Password: